Cargando…
Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
BACKGROUND: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. OBJECTIVES: To establish and quantify the association between isotretinoin use for acne and 1‐year incident...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543533/ https://www.ncbi.nlm.nih.gov/pubmed/35174880 http://dx.doi.org/10.1111/bjd.21049 |
_version_ | 1784804395524816896 |
---|---|
author | Paljarvi, Tapio McPherson, Tess Luciano, Sierra Herttua, Kimmo Fazel, Seena |
author_facet | Paljarvi, Tapio McPherson, Tess Luciano, Sierra Herttua, Kimmo Fazel, Seena |
author_sort | Paljarvi, Tapio |
collection | PubMed |
description | BACKGROUND: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. OBJECTIVES: To establish and quantify the association between isotretinoin use for acne and 1‐year incident neuropsychiatric adverse outcomes. METHODS: A propensity score‐matched cohort study of electronic medical records between the years 2013 and 2019 with patients followed up for 1 year after their index dispensed prescription was conducted. The database included over 12 million patients aged 12–27 years. We analysed data for individuals with acne in this age range with a dispensed prescription for isotretinoin or a control prescription. Outcomes included diagnoses of any incident sleep or mental health disorder, or nonfatal self‐harm within 1 year of the index prescription. RESULTS: We included 30 866 patients prescribed isotretinoin for their acne, 44 748 prescribed oral antibiotics, 108 367 prescribed topical anti‐acne agents and 78 666 patients with acne but without an anti‐acne prescription. After propensity score matching for baseline confounders, the odds ratio (OR) for any incident neuropsychiatric outcomes in patients with acne exposed to isotretinoin was 0·80 [95% confidence interval (CI) 0·74–0·87] compared with those on oral antibiotics; 0·94 (95% CI 0·87–1·02) compared with those using topical anti‐acne medicines; and 1·06 (95% CI 0·97–1·16) compared with those without a prescription for anti‐acne medicines. Patients exposed to isotretinoin experienced significantly more incident physical symptoms than patients in any of the three comparison cohorts. CONCLUSIONS: Isotretinoin was not independently associated with excess adverse neuropsychiatric outcomes at the population level. When monitoring potential adverse outcomes during isotretinoin treatment, clinicians should also consider the high mental health burden associated with treatment‐resistant acne and the potential contribution of physical side‐effects of prescribed medication on mental health. |
format | Online Article Text |
id | pubmed-9543533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95435332022-10-14 Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data Paljarvi, Tapio McPherson, Tess Luciano, Sierra Herttua, Kimmo Fazel, Seena Br J Dermatol Original Articles BACKGROUND: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. OBJECTIVES: To establish and quantify the association between isotretinoin use for acne and 1‐year incident neuropsychiatric adverse outcomes. METHODS: A propensity score‐matched cohort study of electronic medical records between the years 2013 and 2019 with patients followed up for 1 year after their index dispensed prescription was conducted. The database included over 12 million patients aged 12–27 years. We analysed data for individuals with acne in this age range with a dispensed prescription for isotretinoin or a control prescription. Outcomes included diagnoses of any incident sleep or mental health disorder, or nonfatal self‐harm within 1 year of the index prescription. RESULTS: We included 30 866 patients prescribed isotretinoin for their acne, 44 748 prescribed oral antibiotics, 108 367 prescribed topical anti‐acne agents and 78 666 patients with acne but without an anti‐acne prescription. After propensity score matching for baseline confounders, the odds ratio (OR) for any incident neuropsychiatric outcomes in patients with acne exposed to isotretinoin was 0·80 [95% confidence interval (CI) 0·74–0·87] compared with those on oral antibiotics; 0·94 (95% CI 0·87–1·02) compared with those using topical anti‐acne medicines; and 1·06 (95% CI 0·97–1·16) compared with those without a prescription for anti‐acne medicines. Patients exposed to isotretinoin experienced significantly more incident physical symptoms than patients in any of the three comparison cohorts. CONCLUSIONS: Isotretinoin was not independently associated with excess adverse neuropsychiatric outcomes at the population level. When monitoring potential adverse outcomes during isotretinoin treatment, clinicians should also consider the high mental health burden associated with treatment‐resistant acne and the potential contribution of physical side‐effects of prescribed medication on mental health. John Wiley and Sons Inc. 2022-04-12 2022-07 /pmc/articles/PMC9543533/ /pubmed/35174880 http://dx.doi.org/10.1111/bjd.21049 Text en © 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Paljarvi, Tapio McPherson, Tess Luciano, Sierra Herttua, Kimmo Fazel, Seena Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data |
title | Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
|
title_full | Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
|
title_fullStr | Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
|
title_full_unstemmed | Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
|
title_short | Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
|
title_sort | isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543533/ https://www.ncbi.nlm.nih.gov/pubmed/35174880 http://dx.doi.org/10.1111/bjd.21049 |
work_keys_str_mv | AT paljarvitapio isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata AT mcphersontess isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata AT lucianosierra isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata AT herttuakimmo isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata AT fazelseena isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata |